In April 2018, we entered into an asset contribution agreement for Pfizer’s allogeneic CAR T therapy immune-oncology portfolio. We are advancing its allogeneic CAR T cell portfolio acquired from Pfizer, which includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Through our R&D partnerships with Servier and Cellectis, we are leveraging our pioneering technology platform of allogeneic CAR T therapy, or AlloCARs, enhanced by Cellectis’ TALEN® gene editing technology, to advance our portfolio of immuno-oncology therapies.
We are partnering with Servier to initially develop UCART19 for the treatment of adult and pediatric acute lymphoblastic leukemia (ALL). We have exclusive rights to develop and commercialize UCART19 in the United States, while Servier retains exclusive rights for all other countries.
We assumed from Pfizer its strategic collaboration and license agreement with Cellectis, with exclusive rights to develop and commercialize previously defined allogeneic CAR T therapy programs directed at select targets. We expect this alliance with Cellectis to lead to a strong pipeline of allogeneic CAR T therapies, or AlloCARs.